Smith-Magenis syndrome is a genetic disorder caused by a microdeletion involving the retinoic acid-induced 1 (RAI1) gene that maps on the short arm of chromosome 17p11.2 or a pathogenic mutation of RAI1. Smith-Magenis syndrome affects patients through numerous congenital anomalies, intellectual disabilities, behavioral challenges, and sleep disturbances. The sleep abnormalities associated with Smith-Magenis syndrome can include frequent nocturnal arousals, early morning awakenings, and sleep attacks during the day. The sleep problems associated with Smith-Magenis syndrome are attributed to haploinsufficiency of the RAI1 gene. One consequence of reduced function of RAI1, and characteristic of Smith-Magenis syndrome, is an inversion of melatonin secretion resulting in a diurnal rather than nocturnal pattern. Treatment of sleep problems in people with Smith-Magenis syndrome generally involves a combination of sleep hygiene techniques, supplemental melatonin, and/or other medications, such as melatonin receptor agonists, β1-adrenergic antagonists, and stimulant medications, to improve sleep outcomes. Improvement in sleep has been shown to improve behavioral outcomes, which in turn improves the quality of life for both patients and their caregivers.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Edelman EA, Girirajan S, Finucane B, et al. Gender, genotype, and phenotype differences in Smith-Magenis syndrome: a meta-analysis of 105 cases. Clin Genet. 2007;71(6):540–50.
Girirajan S, Vlangos CN, Szomju BB, et al. Genotype–phenotype correlation in Smith-Magenis syndrome: evidence that multiple genes in 17p11.2 contribute to the clinical spectrum. Genet Med. 2006;8(7):417–27.
Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86(5):749–64.
Smith AC, Magenis RE, Elsea SH. Overview of Smith-Magenis syndrome. J Assoc Genet Technol. 2005;31:163–7.
Smith AC, Boyd KE, Brennan C, et al. Smith-Magenis syndrome. Seattle: GeneReviews; 2001.
Elsea SH, Williams SR. Smith-Magenis syndrome: haploinsufficiency of RAI1 results in altered gene regulation in neurological and metabolic pathways. Expert Rev Mol Med. 2011;13:e14.
Laje G, Morse R, Richter W, et al. Autism spectrum features in Smith-Magenis syndrome. Am J Med Genet C Semin Med Genet. 2010;154C:456–62.
Trickett J, Heald M, Oliver C, et al. A cross-syndrome cohort comparison of sleep disturbance in children with Smith-Magenis syndrome, Angelman syndrome, autism spectrum disorder and tuberous sclerosis complex. J Neurodev Disord. 2018;10(1):9.
Shayota BJ, Elsea SH. Behavioral and sleep disturbance in Smith-Magenis syndrome. Curr Opin Psychiatry. 2019;32(2):73–8.
Potocki L, Glaze D, Tan DX, et al. Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome. J Med Genet. 2000;37(6):428–33.
De Leersnyder H. Inverted rhythm of melatonin secretion in Smith-Magenis syndrome: from symptoms to treatment. Trends Endocrinol Metab. 2006;17(7):291–8.
De Leersnyder H, De Blois MC, Vekemans M, et al. β1-Adrenergic antagonists improve sleep and behavioural disturbances in a circadian disorder, Smith-Magenis syndrome. J Med Genet. 2001;38:586–90.
Connor V, Zhao S, Angus R. Non-invasive ventilation for sleep-disordered breathing in Smith-Magenis syndrome. BMJ Case Rep. 2016;bcr2016215621.
Greenberg F, Lewis RA, Potocki L, et al. Multidisciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2). Am J Med Genet. 1996;62:247–54.
Gropman AL, Duncan WC, Smith ACM. Neurologic and developmental features of the Smith-Magenis syndrome (del 17p11.2). Pediatr Neurol. 2006;34:337–50.
Tricket J, Oliver C, Heald M, et al. Sleep in children with Smith-Magenis syndrome: a case–control actigraphy study. Sleep. 2020;43(4):zsz260.
De Leersnyder H, de Blois M-C, Claustrat B, et al. Inversion of the circadian rhythm of melatonin in the Smith-Magenis syndrome. J Pediatr. 2001;139:111–6.
Duncan WC, Gropman A, Morse RS, et al. Good babies sleeping poorly; insufficient sleep in infants with Smith-Magenis syndrome. Am J Hum Genet. 2003;73:A896.
Smith AM, Morse RS, Introne W, et al. Twenty-four-hour motor activity and body temperature patterns suggest altered central circadian timekeeping in Smith-Magenis syndrome, a neurodevelopmental disorder. Am J Med Genet A. 2019;179(2):224–36.
Gropman AL, Elsea S, Duncan WC Jr, et al. New developments in Smith-Magenis syndrome (del 17p11.2). Curr Opin Neurol. 2007;20:125–34.
Smith-Magenis Syndrome Foundation UK. 2019. https://www.smith-magenis.org/what-is-sms/sleep-and-sms/. Accessed 31 Jul 2019.
Williams SR, Zies D, Mullegama SV, et al. Smith-Magenis syndrome results in disruption of CLOCK gene transcription and reveals an integral role for RAI1 in the maintenance of circadian rhythmicity. Am J Hum Genet. 2010;90(6):941–9.
Mullegama SV, Alaimo JT, Fountain MD, et al. RAI1 overexpression promotes altered circadian gene expression and dyssomnia in Potocki-Lupski syndrome. J Pediatr Genet. 2017;6(3):155–64.
Gillette MU, Tischkau SA. Suprachiasmatic nucleus: the brain’s circadian clock. Recent Prog Horm Res. 1999;54:58–9.
Hardeland R. Chronobiology of melatonin beyond the feedback to the suprachiasmatic nucleus-consequences of melatonin dysfunction. Int J Mol Sci. 2013;14(3):5817–41.
Boone PM, Reiter RJ, Glaze DG, et al. Abnormal circadian rhythm of melatonin in Smith-Magenis syndrome patients with RAI1 point mutations. Am J Med Genet A. 2011;155A(8):2024–7.
Poisson A, Nicolas A, Bousquet I, et al. Smith-Magenis syndrome: molecular basis of a genetic-driven melatonin circadian secretion disorder. Int J Mol Sci. 2019;20:3533.
Barboni ST, Bueno C, Nagy BV, Maia PL, Vidal KS, Alves RC, et al. Melanopsin system dysfunction in Smith-Magenis syndrome patients. Investig Ophthalmol Vis Sci. 2018;59(1):362–9.
Chen L, Mullegama SV, Alaimo JT, et al. Smith-Magenis syndrome and its circadian influence on development, behavior, and obesity: own experience. Dev Period Med. 2015;19(2):149–56.
PRISMS. Parents and researchers interested in Smith-Magenis syndrome. 2019. www.prisms.org/wpcontent/uploads/pdf/mmg/PRISMS_Medical_Management_Guidelines2018.pdf. Accessed 31 Jul 2019.
Dubocovich ML. Melatonin receptors: role of sleep and circadian rhythm on regulation. Sleep Med. 2007;8(Suppl. 3):34–42.
Costello RB, Lentino CV, Boyd CC, et al. The effectiveness of melatonin for promoting healthy sleep: a rapid evidence assessment of the literature. Nutr J. 2014;7(13):106.
Spruyt K, Braam W, Smits M, et al. Sleep complaints and the 24-h melatonin level in individuals with Smith-Magenis syndrome: assessment for effective intervention. CNS Neurosci Ther. 2016;22(11):928–35.
Andersen LP, Gögenur I, Rosenberg J, et al. The safety of melatonin in humans. Clin Drug Investig. 2016;36(3):169–75.
Kennaway D. Potential safety issues in the use of the hormone melatonin in paediatrics. J Paediatr Child Health. 2015;51(6):584–9.
Erland LA, Saxena PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. J Clin Sleep Med. 2017;13(2):275–81.
Hardeland R. Melatonin in aging and disease: multiple consequences of reduced secretion, options and limits of treatment. Aging Dis. 2012;3:194–225.
Gringras P, Nir T, Breddy J, et al. Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2017;56(11):948–57.
McGechan A, Wellington K. Ramelteon. CNS Drugs. 2005;19:1057–65.
Neubauer DN. A review of ramelteon in the treatment of sleep disorders. Neuropsychiatr Dis Treat. 2008;4(1):69–79.
Baek WS, Elsea SH. Smith-Magenis syndrome treated with ramelteon and amphetamine–dextroamphetamine: case report and review of the literature. J Genet Disord Genet Resp. 2016;5:4.
Lavendan C, Forsberg M, Gentile AJ. Tasimelteon: a selective and unique receptor binding profile. Neuropharmacology. 2015;91:142–7.
Hetlioz® [package insert]. Washington, DC: Vanda Pharmaceuticals, Inc.; 2014.
Hull JT, Polymeropoulos H, Xiao C, et al. Tasimelteon improves sleep quality and behavior in individuals with Smith-Magenis syndrome (SMS) in an open-label study. Sleep. 2019;42:A255.
Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol. 2007;10:691–6.
Sansone R, Sansone L. Agomelatine; a novel antidepressant. Innov Clin Neurosci. 2011;8(11):10–4.
Stoschitzky K, Sakotnik A, Lercher P, et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol. 1999;55:111–5.
De Leersnyder H, Bresson JL, de Blois M, et al. β1-Adrenergic antagonists and melatonin reset the clock and restore sleep in a circadian disorder, Smith-Magenis syndrome. J Med Genet. 2003;40:74–8.
Carpizo R, Martinez A, Mediavilla D, et al. Smith-Magenis syndrome: a case report of improved sleep after treatment with β1-adrenergic antagonists and melatonin. J Peds. 2006;149(3):409–11.
Banerjee D, Vitiello MV, Grunstein RR, et al. Pharmacotherapy for excessive daytime sleepiness. Sleep Med Rev. 2004;8(5):339–54.
Laje G, Bernert R, Morse R, et al. Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome. Am J Med Genet C Semin Med Genet. 2010;154C(4):463–8.
Morin CM, Koetter U, Bastien C, et al. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep. 2005;28(11):1465–71.
Glass JR, Sproule BA, Herrmann N, et al. Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial. J Clin Psychopharmacol. 2008;28(2):182–8.
Katayose Y, Aritake S, Kitamura S, et al. Carryover effect on next-day sleepiness and psychomotor performance of nighttime administered antihistaminic drugs: a randomized controlled trial. Hum Psychopharmacol. 2012;27(4):428–36.
Jamadarkhana S, Gopal S. Clonidine in adults as a sedative agent in the intensive care unit. J Anaesthesiol Clin Pharmacol. 2010;26(4):439–45.
Prince JB, Wilens TE, Biederman J, et al. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry. 1996;35(5):599–605.
Jaffer KY, Chang T, Vanle B, et al. Trazodone for insomnia: a systematic review. Innov Clin Neurosci. 2017;14(7–8):24–34.
Wichniak A, Wierzbicka A, Sobanska A, et al. The effectiveness of treatment with trazodone in patients with primary insomnia without and with prior history of hypnotics use. Pol Merkur Lekarski. 2007;23(133):41–6.
Gugger J, Cassagnol M. Low-dose quetiapine is not a benign sedative hypnotic agent. Am J Addict. 2008;17:454–5.
No funding sources were used for the preparation of this article.
Conflict of interest
Sarah H. Elsea receives research funding from the Smith-Magenis Syndrome Research Foundation, PRISMS, Inc., Fondation Jerome Lejeune, Rhythm Therapeutics, and Vanda Pharmaceuticals. Kevin A. Kaplan and Lorraine Potocki have no conflicts of interest that are directly relevant to the content of this article.
About this article
Cite this article
Kaplan, K.A., Elsea, S.H. & Potocki, L. Management of Sleep Disturbances Associated with Smith-Magenis Syndrome. CNS Drugs 34, 723–730 (2020). https://doi.org/10.1007/s40263-020-00733-5